All posts by Saami Zakaria

Saami Zakaria is a neurology resident physician in New York City who has long been interested in the intersection of the brain and the machine and how it can be responsibly shaped. Additionally, he is enthusiastic about appraising evidence for clinical trials and the various methodologies used in medicine to ensure our practices are truly patient-centric. Many of his writings can be found on his substack. He can also be found on X (formerly known as Twitter) as @SaamiJZ

All Posts

Author

  • Saami Zakaria is a neurology resident physician in New York City who has long been interested in the intersection of the brain and the machine and how it can be responsibly shaped. Additionally, he is enthusiastic about appraising evidence for clinical trials and the various methodologies used in medicine to ensure our practices are truly patient-centric. Many of his writings can be found on his substack. He can also be found on X (formerly known as Twitter) as @SaamiJZ

    View all posts
Alzheimer's DiseaseClinical TrialsNeuroscience/Mental Health

FDA Advisory Committee Recommends approval of new Alzheimer’s drug Donanemab

If approved, donanemab would be the third FDA approved disease-modifying beta-amyloid treatment for Alzheimer’s disease.

/ June 23, 2024